Nektar partners with TrialNet for Phase 2 study of rezpegaldesleukin in type 1 diabetes

NEKTAR THERAPEUTICS

TrialNet will conduct a Phase 2 randomized, placebo-controlled trial in ~70 adults and children with new onset stage 3 T1D.
Nektar supplies rezpegaldesleukin, retains all program rights; TrialNet funds the study via NIH.
Study aims to preserve beta-cell function using MMTT-measured C-peptide over 12 months; initiation targeted for 2025.
Rezpegaldesleukin is also in Phase 2b trials for atopic dermatitis (REZOLVE-AD) and alopecia areata (REZOLVE-AA).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.